Biogen Sees At Least Six Tecfidera Generics And 90% Discounts
Pace Of Erosion ‘Difficult To Predict’
Executive Summary
Biogen counted the cost of losing its monopoly on Tecfidera in the third quarter, with multiple generic entrants rushing in to the multi-billion-dollar opportunity.